Google
HCWB Stock Price & Analysis — HCW Biologics Inc (Healthcare >> Biotechnology)
HCWB FAQ
What is HCWB's P/E ratio?
HCW Biologics Inc (HCWB) currently trades at a P/E ratio of 1.13.
What is HCWB's ROE?
HCW Biologics Inc reports a Return on Equity (ROE) of -28.29%.
What is HCWB's dividend yield?
HCW Biologics Inc offers a dividend yield of 0.00%.
What is HCWB's Quality Score?
Our AI rates HCWB's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy HCWB?
Our AI Timing Score for HCWB is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does HCWB belong to?
HCW Biologics Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
HCWB AI Analysis Summary
Our AI summary for HCWB: HCW Biologics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 1.13, ROE of -28.29%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 3.41
Price
-0.02
(-0.58%)
Day Change
|
|
|---|
HCWB, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 3.41 |
| PBV / Sector |
0.95 / 5.21
GREAT
|
| Earning Per Share | -1.01 |
| PE / Sector |
1.13 / 21.00
GREAT
|
| PEG or PE/Growth / Sector |
0.01 / 1.11
GREAT
|
| Average 1M Daily Value |
0.24 M
GREAT
|
| Average 1W Daily Value |
0.34 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
47% |
| Ability to Make Profit |
|
64% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-07 08:11:47 |
| Symbol | HCWB |
| Name | HCW BIOLOGICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 1.60 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 5.48 / 9,672.56 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2929 North Commerce Parkway, Miramar, FL, United States, 33025
Phone: 954 842 2024
Website: https://www.hcwbiologics.com
Sector: Healthcare >> Biotechnology
Description: HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, a multi-functional immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecule. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap